| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention relates to novel compound, namely to N-(5-chlorfuran-2-ylcarbonyl)-3,7-diazabicyclo[3.3.0]octane or its pharmaceutically acceptable salts, pharmaceutical compositions for treatment of conditions and disorders associated with dysfunction of central nervous system, containing said compound, as well as methods of treatment. Claimed compound demonstrates selectivity with respect to neuron nicotine receptors of subtype α4β2 in central nervous system (CNS) and bind with them with high affinity. n EFFECT: compound and compositions based on it can be applied for treatment and/or prevention of wide spectrum of diseases and disorders, in particular, CNS disorders. n 6 cl, 1 tbl, 11 ex |